Today at #ESMO2026, PCC’s Kristen Spencer, DO, (@kspencer725) presents research on novel targeted therapies for colorectal cancer, including KRAS G12D inhibitors and treatment appr

Perlmutter Cancer Center at NYU Langone Health· @Perlmutter_CC · X·2026-10-24 20:00· 1 day agoScore45

Body · original

Today at #ESMO2026, PCC’s Kristen Spencer, DO, (@kspencer725) presents research on novel targeted therapies for colorectal cancer, including KRAS G12D inhibitors and treatment approaches for MCC CRC.

@myESMO @nyugrossman

4 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

1039PNCT05067283 NCT05067283 NCT05067283matched by Developmental therapeutics

Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study

https://esmocongress.esmo.org

2551TIPNCT07541170 NCT07541170 NCT07541170matched by NSCLC, early stage

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

2683Pmatched by NSCLC, metastatic

First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01

https://esmocongress.esmo.org

Source: Perlmutter Cancer Center at NYU Langone Health · x.com